Search This Blog

Tuesday, November 1, 2016

New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma | BMS Newsroom

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced new data presentations from studies evaluating Opdivo (nivolumab) as monotherapy or in combination with Yervoy (ipilimumab) in the treatment of melanoma, including new research on the efficacy and safety of the combination in melanoma patients with high unmet need including those with elevated serum lactate dehydrogenase (LDH) and brain metastases. Additional presentations will also highlight new data on health economics and real-world outcomes in patients living with the disease.



New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma | BMS Newsroom

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.